These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36162740)

  • 21. Preferred product attributes of a multipurpose vaginal ring: Findings from a phase 1 trial.
    Tolley EE; Hanif H; Thurman A; Brache V; Doncel GF
    Front Reprod Health; 2023; 5():1148134. PubMed ID: 37064825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.
    Watnick D; Keller MJ; Stein K; Bauman LJ
    AIDS Behav; 2018 Feb; 22(2):421-436. PubMed ID: 29147810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.
    Ugaonkar SR; Wesenberg A; Wilk J; Seidor S; Mizenina O; Kizima L; Rodriguez A; Zhang S; Levendosky K; Kenney J; Aravantinou M; Derby N; Grasperge B; Gettie A; Blanchard J; Kumar N; Roberts K; Robbiani M; Fernández-Romero JA; Zydowsky TM
    J Control Release; 2015 Sep; 213():57-68. PubMed ID: 26091920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications.
    Palanee-Phillips T; Baum MM; Moss JA; Clark MR; Nuttall J; Romano JW
    Expert Opin Drug Deliv; 2022 Jan; 19(1):47-58. PubMed ID: 34958283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of women screened for a contraceptive intravaginal ring study in Kisumu, Kenya, 2014.
    McLellan-Lemal E; Gust DA; Gvetadze R; Furtado M; Otieno FO; Desai M; Zeh C; Samandari T; Nyagol B; Makanga EM
    Res J Womens Health; 2016; 3():. PubMed ID: 27441094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
    Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
    Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multipurpose prevention technologies: products in development.
    Friend DR; Clark JT; Kiser PF; Clark MR
    Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
    Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
    PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.
    van der Straten A; Montgomery ET; Cheng H; Wegner L; Masenga G; von Mollendorf C; Bekker L; Ganesh S; Young K; Romano J; Nel A; Woodsong C
    AIDS Behav; 2012 Oct; 16(7):1775-86. PubMed ID: 22644068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.
    Weinrib R; Minnis A; Agot K; Ahmed K; Owino F; Manenzhe K; Cheng H; van der Straten A
    AIDS Behav; 2018 Jan; 22(1):133-145. PubMed ID: 29052018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
    van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
    J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.
    Derby N; Aravantinou M; Kenney J; Ugaonkar SR; Wesenberg A; Wilk J; Kizima L; Rodriguez A; Zhang S; Mizenina O; Levendosky K; Cooney ML; Seidor S; Gettie A; Grasperge B; Blanchard J; Piatak M; Lifson JD; Fernández-Romero J; Zydowsky TM; Robbiani M
    Drug Deliv Transl Res; 2017 Dec; 7(6):840-858. PubMed ID: 28600625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
    PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
    Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
    Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.